At Harmonic Pharma, we believe that the polypharmacology based technology that we have developed
is a powerful way of revisiting safe drugs by de-risking R&D and accelerating market access.
We aggregate information from diverse sources to drugs with a special concern about drug safety and generate relevant disease related data for the selected indication. Our business model combines our core know-how with outsourcing and critical partnering to produce synergies and a strong IP position.
As our new technology and know-how allow to deliver results more cost effectively than in the past few years, innovative business opportunities are explored with interested stakeholders.
For instance, it makes it possible for public or private organizations to fund the early clinical phase that is necessary to get a Proof of Concept (PoC) in man – for the newly identified indication – so that it can then be further developed and marketed by biotech and pharma companies.